Histotype-genotype correlation in 36 high-grade endometrial carcinomas

American Journal of Surgical Pathology

Volumn 37, Issue 9, 2013, Pages 1421-1432

  Hoang, Lien N ^a,b   McConechy, Melissa K ^a,b   Köbel, Martin ^c   Han, Guangming ^d   Rouzbahman, Marjan ^d   Davidson, Ben ^e   Irving, Julie ^a,b   Ali, Rola H ^a,b   Leung, Sam ^a,b   McAlpine, Jessica N ^a   Oliva, Esther ^f   Nucci, Marisa R ^g   Soslow, Robert A ^h   Huntsman, David G ^a,b   Gilks, C Blake ^a,b   Lee, Cheng Han ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF OSLO   (Norway)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

ARID1A; Endometrial cancer; Endometrioid carcinoma; PPP2R1A; PTEN; Serous carcinoma; TP53

Indexed keywords

ARID1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; ESTROGEN RECEPTOR; NUCLEAR PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE 2; PPP2R1A PROTEIN, HUMAN; PROTEIN P53; PTEN PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BIOPSY; CANCER GRADING; CARCINOMA; CHEMISTRY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; NEOPLASM; NUCLEOTIDE SEQUENCE; OBSERVER VARIATION; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; REPRODUCIBILITY; TISSUE MICROARRAY; VERY ELDERLY;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CARCINOMA; CARCINOMA, ENDOMETRIOID; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUTATION; NEOPLASM GRADING; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; NUCLEAR PROTEINS; OBSERVER VARIATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROTEIN PHOSPHATASE 2; PTEN PHOSPHOHYDROLASE; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84884521211     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31828c63ed     Document Type: Article

References (38)

1. Bray F, Dos Santos Silva I, Moller H, et al. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev. 2005;14: 1132-1142.
2. Evans T, Sany O, Pearmain P, et al. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer. 2011;104:1505-1510.
3. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127: 2893-2917.
4. Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics-2012. CA Cancer J Clin. 2012;62:220-241.
5. Silverberg SG, Mutter GL, Kurman RJ, et al. Tumors of the Breast and Female Genital Organs: World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2003.
6. Clarke BA, Gilks CB. Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type. J Clin Pathol. 2010;63:410-415.
7. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005;366:491-505.
8. Amant F, Moerman P, Neven P, et al. Treatment modalities in endometrial cancer. Curr Opin Oncol. 2007;19:479-485.
9. Prat J. Prognostic parameters of endometrial carcinoma. Hum Pathol. 2004;35:649-662.
10. Garg K, Leitao MM Jr, Wynveen CA, et al. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol. 2010;23:80-92.
11. Lomo L, Nucci MR, Lee KR, et al. Histologic and immunohistochemical decision-making in endometrial adenocarcinoma. Mod Pathol. 2008;21:937-942.
12. Gilks B, Oliva E, Soslow RA. Poor inter-observer reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol. 2012. In pres.s.
13. Sidhu D, Duggan M, Clement P, et al. Interobserver agreement on high-grade endometrial carcinoma and correlation with ER, p53 and p16 expression (USCAP 20120 annual meeting abstract no. 1246). Mod Pathol. 2012;25:296A.
14. Bartosch C, Manuel Lopes J, Oliva E. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Adv Anat Pathol. 2011;18:415-437.
15. Garg K, Soslow RA. Strategies for distinguishing low-grade endometrioid and serous carcinomas of endometrium. Adv Anat Pathol. 2012;19:1-10.
16. Soslow RA. Endometrial carcinomas with ambiguous features. Semin Diagn Pathol. 2010;27:261-273.
17. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol. 2004;28:1568-1578.
18. Alkushi A, Kobel M, Kalloger SE, et al. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol. 2010;29:343-350.
19. Yemelyanova A, Ji H, Shih Ie M, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol. 2009;33:1504-1514.
20. Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011;35:625-632.
21. McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012;228:20-30.
22. O'Hara AJ, Bell DW. The genomics and genetics of endometrial cancer. Adv Genomics Genet. 2012;2012:33-47.
23. Okuda T, Sekizawa A, Purwosunu Y, et al. Genetics of endometrial cancers. Obstet Gynecol Int. 2010;2010:984013.
24. Samarnthai N, Hall K, Yeh IT. Molecular profiling of endometrial malignancies. Obstet Gynecol Int. 2010;2010:162363.
25. Tashiro H, Blazes MS, Wu R, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res. 1997;57:3935-3940.
26. McConechy MK, Anglesio MS, Kalloger SE, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol. 2011;223:567-573.
27. Shih IeM, Panuganti PK, Kuo KT, et al. Somatic mutations of PPP2R1A in ovarian and uterine carcinomas. Am J Pathol. 2011;178:1442-1447.
28. An HJ, Logani S, Isacson C, et al. Molecular characterization of uterine clear cell carcinoma. Mod Pathol. 2004;17:530-537.
29. Le Gallo M, O'Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet. 2012;44:1310-1315.
30. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363:1532-1543.
31. Jones S, Wang TL, Shih Ie M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228-231.
32. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37-46.
33. Zaino RJ, Kurman RJ, Brunetto VL, et al. Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a gynecologic oncology group study. Am J Surg Pathol. 1998;22:1379-1385.
34. Soslow RA. High-grade endometrial carcinomas: strategies for typing. Histopathology. 2013;62:89-110.
35. Cirisano FD Jr, Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol. 2000;77:55-65.
36. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94: 642-646.
37. Soslow RA, Bissonnette JP, Wilton A, et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol. 2007;31:979-987.
38. Voss MA, Ganesan R, Ludeman L, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol. 2012;124:15-20.